Latest Conference

Presenters combed through the barrage of clinical trials to share those that could be practice-changing for clinicians.

Christopher McCoy, PharmD, shares the protocol for approaching patients who may have a beta-lactam allergy.

Prolonged antibiotic use opens the door to the development of antibiotic resistance, superinfections, and the risk of Clostridium difficile infections.

The message for clinicians is to be vigilant. Look for candidemia and C. difficile infection occurring together.

Sue Cammarata, MD, explains the advantages that delafloxcin has over other fluoroquinolones.

Using combination antifungal therapy for invasive mold diseases is still a grey area that remains to be supported by robust data and relies heavily on clinician assessment.

Thoughts leaders believe infectious disease treatment is in the middle of a sea change, moving from antibiotics to antibodies.

Neil Fishman, MD, explains what the standardized antimicrobial administration ratio is.

Researchers found that the use of the treatment algorithm for staphylococcal bacteremia shortens therapy without compromising outcomes.

Whether the oft-repeated pattern of initial drug success followed by increasing resistance plays out in the future for many drugs remains to be seen.

David Andes, MD, shares the half-life and dosing intervals for a new long-acting echinocandin.

About 500,000 Americans fall ill from Clostridium difficile infections every year.

Dr. Maria Bye, an epidemiologist at the Minnesota Department of Health shares some unsettling news when it comes to C. difficile: dentists’ prescribing habits may be contributing to CDI incidence.

David Huang, PhD, MD, shares the recent results of the REVIVE-2 trial.

Candidemia is the most common healthcare-associated bloodstream infection in the United States, with an incidence of 5-15 per 100,000 persons.

Patrick Horn, MD, PhD, explains why eravacycline is a unique antibiotic and how it stands up against many different types of pathogens, including those that are multidrug-resistant.

It is only a matter of time before the next infectious disease pandemic hits and healthcare officials need to be prepared.

Dr. Monique Foster, CDC, and Dr. Eric McDonald, San Diego County Health and Human Services Agency, discuss the surprising return of hepatitis A virus as part of the Late Breakers I symposium.

James S. Lewis, PharmD, FIDSA, addresses the issues that surround current antibiotic development.

Viviane Boaventura, MD, MsC, PhD, explains how Zika virus causes auditory loss.

Alan Gross, PharmD, explains how a neural network can help identify patients who are at increased risk for multidrug-resistant pathogens.

Silvia Munoz-Price, MD, PhD, explains why infection control bundles should evolve as the problems faced by hospital epidemiologists continue to change.

Alex Rinehart, PhD, explains how the development of a long-acting injectable offers a new preventive option for HIV.

Contagion® will be providing exclusive coverage on the conference, and so, keep your eyes peeled for session coverage and interviews with some of the key presenters.

David A. Schwartz, MD, MS Hyg, FCAP, explains how researchers from all over the world have come together to share their research on Zika virus.

Silvio Pitlik, MD, provides insight into the prevalence of Lyme disease in Israel.

Prof. Francisco Veas, PhD, chief security officer, Institut de Recherche pour le Développement, France, explains some of the issues faced by patients with Lyme disease living in Europe.

Hanneke Schuitemaker, PhD, explains the challenges faced when creating a vaccine for HIV.